Digital Pathology Market Growth & Trends

The global Digital Pathology Market size is anticipated to reach USD 1.73 billion by 2030, anticipated to register a CAGR of 8.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness exponential growth owing to rising prevalence of chronic diseases aided by increasing demand for accurate diagnostics. Chronic diseases affect nearly one in every three adults. Whereas, according to the CDC, in the U.S., approximately, 51.8% of adults have at least one chronic disease. Digital pathology, including molecular tissue profiling, biobanking, tissue microarray analysis, and molecular biology, plays an important role in the drug development pipeline and companion diagnostics. Growing demand for high-quality tissue samples in tissue-based biomarker research is expected to drive technology adoption over the forecast period.

Increasing adoption of telepathology with the launch of newer versions of the technology, such as in June 2022, Tribun Health launched TeleSlide Patho 5, an online telepathology platform used for providing clinical and timely expertise to patients. Moreover, the market is expected to see intense competition in the near future as companies adopt more stringent strategies to compete. Moreover, technological advancements, such as the digitization of pathology lab makes the specialty more efficient, the specimen more reproducible, and pathologists’ work easier. In past few years, several breakthrough advancements have provided a significant boost to market growth.

For instance, in September 2021, Paige received FDA approval for Paige Prostate, an AI solution for the detection of prostate cancer. The product is the first AI-enabled pathology product to gain marketing authorization. This was further followed by the collaboration of F. Hoffmann-La Roche Ltd. with Ibex in October 2021 for the development of artificial intelligence-based pathology applications for the improvement of patient care. Furthermore, major players are adopting strategies like collaborations and partnerships with a focus on technological advancements, such as robotic light microscopy, digital imaging, multiple fiber optic communications, and computerization, to enhance the adoption of digital pathology.

For instance, in December 2022, Deciphex launched Patholytix 3.0, a Digital Research Pathology Platform with an aim to revolutionize tools available for research pathologists and designed to overcome the limits of LIMS software that allows users to effectively manage associated data and samples. Furthermore, with the launch, the company also highlighted features of the new platform that impact workflow and offer simpler and more expedient report creation.

Request a free sample copy or view report summary: 
Digital Pathology Market Report

Digital Pathology Market Report Highlights

• Based on product, the device segment held the largest revenue share in 2023. The device segment includes a slide management system and scanner. The segment growth is attributed to the increasing adoption of digital pathology in academic research activities with enhanced resolution
• Based on application, the disease diagnosis segment is anticipated to grow at the fastest CAGR over the forecast period due to an increasing prevalence of chronic diseases and demand for noble diagnosis techniques
• In terms of end-use, the hospitals segment held the largest revenue share in 2023 due to the growing incorporation of digital pathologies in healthcare settings for efficient disease diagnosis
• North America region dominated the market in 2023, due to the presence of well-established digital infrastructure and several technological advancements pertaining to the incorporation of technology in healthcare settings

List of Key Players in the Digital Pathology Market

• Leica Biosystems Nussloch GmbH (Danaher)
• Hamamatsu Photonics, Inc.
• Koninklijke Philips N.V.
• Olympus Corporation
• F. Hoffmann-La Roche Ltd.
• Mikroscan Technologies, Inc.
• Inspirata, Inc.
• Epredia (3DHISTECH Ltd.)
• Visiopharm A/S
• Huron Technologies International Inc.
• ContextVision AB